PhaseV News
17 articles
/PRNewswire/ -- PhaseV, a leader in AI/ML for clinical development, today announced it will participate in several upcoming biopharma conferences shaping the...
PhaseV, a leader in AI/ML for clinical development, is set to participate in several biopharma conferences to showcase their expertise in next-generation Bayesian and causal AI. These technologies enhance the flexibility, robustness, and speed of clinical trials. The company aims to reduce risk and accelerate the path to market for sponsors. PhaseVs platform has significantly reduced trial costs and durations while increasing the probability of trial success. The company will present at various events, including the Pharma Tech Forum, ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Fierce Biotech Week, and Bayesian Biostatistics Conference. PhaseVs solutions are being leveraged by over 40 leading pharma/biotech sponsors and CROs across multiple therapeutic areas.
/PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced a strategic partnership with the Crohn's & Colitis Foundation, the...
PhaseV has announced a strategic partnership with the Crohns & Colitis Foundation to advance research and development in inflammatory bowel disease (IBD) treatments. By leveraging the Foundations IBD Plexus® Research Accelerator and PhaseVs AI/ML solutions, the collaboration aims to overcome challenges in clinical development and enhance personalized treatment strategies. This partnership will help biopharma sponsors design more flexible, patient-centric trials, potentially leading to more effective IBD therapies. The collaboration reflects a commitment to addressing the complexities of IBD and improving patient outcomes through innovative trial designs and data-driven approaches.
Partners
PhaseV raises $50 million Series A to rethink how drugs get to market | CTech
PhaseV, an Israeli startup, has raised $50 million in a Series A funding round co-led by Accel and Insight Partners, with participation from Viola Ventures, EXOR, and LionBird. This brings the companys total funding to $65 million. PhaseV is leveraging artificial intelligence to enhance clinical trial design and execution, aiming to reduce the high costs and slow timelines traditionally associated with drug development. The company has already secured over 30 global customers, including major pharmaceutical firms, indicating strong demand for its AI-powered platform. PhaseVs approach focuses on a vertical AI platform tailored specifically for clinical research, offering features like adaptive trial design and real-time cohort optimization.
InvestmentCustomers
הסטארט־אפ PhaseV הוקם לפני פחות משנתיים, כבר משרת עשרות חברות פארמה ברחבי העולם — והשלים סבב גיוס של 50 מיליון דולר בהובלת קרנות בולטות ■ הטכנולוגיה שפיתח מזהה אילו ניסויים קליניים נכשלים לא מפני שהתרופה לא עובדת, אלא מפני שהם לא תוכננו או פוענחו בצורה נכונה
PhaseV, a startup founded less than two years ago, has successfully raised $50 million in a funding round led by prominent funds. The company serves dozens of pharmaceutical companies worldwide. PhaseV has developed technology that identifies why certain clinical trials fail, not because the drug is ineffective, but due to improper design or analysis. This investment is expected to further enhance their capabilities and expand their reach in the pharmaceutical industry.
InvestmentCustomers
/PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced the completion of a $50 million Series A funding round. Co-led by Accel...
PhaseV, a leader in AI/ML-driven clinical development, has raised $50 million in a Series A funding round co-led by Accel and Insight Partners, with participation from existing investors. The funding will support the expansion of PhaseVs vertical AI platform, which is already used by over 30 global pharma companies across more than 20 therapeutic areas. The platform has demonstrated significant reductions in trial costs and durations, and an increase in trial success rates. PhaseVs technology is poised to transform clinical development by optimizing trial design and execution, and the company plans to add more capabilities to its platform.
InvestmentCustomersPartners
/PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced that the second episode in its webinar series will focus on improving...
PhaseV, a leader in AI/ML-driven clinical development, announced a webinar focusing on patient-centricity and efficiency in clinical trial design. The webinar, scheduled for May 1, 2025, will feature industry leaders discussing adaptive trial design and the integration of real-world data to improve patient stratification and trial results. PhaseVs platform, which optimizes clinical development through AI/ML solutions, has significantly reduced trial costs and duration while increasing success probability. The company has collaborated with over 30 leading pharma/biotech sponsors and CROs across various therapeutic areas. The webinar aims to share insights and strategies for incorporating AI-driven approaches and patient-centered design into clinical trials.
/PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced its participation in several upcoming biotech and data science...
PhaseV, a leader in AI/ML-driven clinical development, is set to participate in several biotech and data science conferences to showcase its advancements in optimizing clinical trials. The company uses AI-powered analytics and biostatistics to enhance trial efficiency, regulatory adherence, and accelerate treatments for various diseases. PhaseVs platform has been adopted by over 30 global pharmaceutical and biotech companies, reducing trial costs and increasing success probabilities. The company will present at events like IBD Innovate 2025, Duke Industry Statistics Symposium, and others, highlighting its innovative approaches in clinical trial design and execution.
Product StageCustomers
CEO and Co-Founder Dr. Raviv Pryluk spoke to CTech after being named as one of the Top 10 Israeli startups to watch out for in 2025 at Calcalist’s Mind The Tech conference in New York.
PhaseV, an AI software company founded in 2023, aims to optimize clinical development processes. The company, based in Boston and Tel Aviv, was highlighted as one of the Top 10 Israeli startups to watch in 2025 at Calcalist’s Mind The Tech conference in New York. PhaseVs platform enhances the efficiency and effectiveness of drugs and clinical trials, addressing the high failure rate in clinical trials. The company has raised $15 million to date, with Qumra Capital being a notable investor. PhaseVs AI platform helps sponsors, pharma companies, biotech, and CROs make better decisions, thereby increasing the probability of success in clinical trials.
Investment
/PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, announced today that it will demonstrate new capabilities of its platform for clinical...
PhaseV, a leader in AI/ML-driven clinical development, is set to showcase its latest platform advancements at the CMO Summit 360⁰ in Boston. The platform integrates causal machine learning and AI to enhance trial design and predictive analysis for clinical trial success. By leveraging real-world data and insights from previous trials, PhaseV aims to optimize trial investments, reduce failure rates, and improve patient outcomes. The platforms unique capabilities, including Causal to Adaptive and Clinical Trial Success Prediction, enable real-time evaluation and informed decision-making. PhaseV has already delivered results for over 30 leading pharma/biotech sponsors and CROs, achieving significant reductions in trial costs, enrollment size, and duration.
Product StageCustomers
/PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for advanced clinical development optimization, announced today the launch of its new...
PhaseV, a leader in software and machine learning for clinical development, has announced a new webinar series focusing on innovations in clinical trial design and execution. The series will explore the transformative impact of AI, real-world evidence, and predictive analytics in clinical development. The inaugural session will feature industry experts discussing AI-driven patient selection, Bayesian and adaptive trial designs, and the use of real-world data to improve trial design and decision-making. The webinar aims to enhance efficiency, improve decision-making, and increase trial success rates by integrating AI-powered strategies. PhaseVs technology is designed to optimize adaptive clinical trials, increasing their efficiency and success rates.
/PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for advanced clinical development optimization, announced today that senior company...
PhaseV, a leader in software and machine learning for clinical development, is set to present at five major industry conferences in early 2025. The company will showcase its expertise in causal inference and adaptive machine learning tools that enhance clinical trial efficiency and success. PhaseVs technology optimizes clinical trials by detecting hidden signals in data, thus improving design and execution. The company has established partnerships with over 30 global pharma and biotech companies, including seven industry leaders. These collaborations highlight PhaseVs role in advancing clinical trial methodologies to bring new treatments to patients more efficiently.
PartnersCustomers
/PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today it has entered a strategic partnership...
PhaseV, a leader in software and machine learning for clinical trial optimization, has partnered with Alimentiv Inc., a global gastrointestinal contract research organization. This strategic partnership aims to enhance the design and execution of adaptive clinical trials for gastrointestinal conditions such as inflammatory bowel disease and celiac disease. By integrating PhaseVs advanced machine learning capabilities with Alimentivs expertise in GI trials, the collaboration seeks to improve clinical study efficiency and outcomes. This partnership is expected to accelerate the development of new GI therapies and address the growing burden of GI diseases more effectively.
Partners
/PRNewswire/ -- PhaseV, a leader in software and machine learning (ML) for advanced clinical development optimization, today announced it has partnered with...
PhaseV, a leader in software and machine learning for clinical development optimization, has partnered with University Health Network (UHN) to develop a machine learning-driven solution for systemic lupus erythematosus (SLE). The collaboration aims to improve understanding of the diseases heterogeneity and enhance drug development. PhaseVs Causal-ML platform will model disease progression and treatment response variability, providing insights for more effective clinical trial designs. This partnership is expected to increase the success rates of SLE therapies by optimizing trial designs and patient selection.
Partners
/PRNewswire/ -- PhaseV, a leader in software and machine learning (ML) for advanced clinical development optimization, today announced it has partnered with...
PhaseV, a leader in software and machine learning for clinical development, has partnered with the University Health Network (UHN) to develop a machine learning-driven solution to address challenges in systemic lupus erythematosus (SLE) treatment. The collaboration aims to improve understanding of lupus heterogeneity and optimize clinical trial design, potentially leading to more effective therapies. PhaseVs Causal-ML platform uses advanced algorithms to model disease progression and treatment variability, providing insights for more precise clinical trials. This partnership with UHN, a global leader in SLE research, is expected to enhance drug development success rates for lupus patients.
Partners
/PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today the latest capabilities of its AdaptV...
PhaseV, a leader in software and machine learning for clinical trial optimization, has announced new capabilities for its AdaptV platform to enhance the efficiency and success rates of oncology clinical trials. The platform uses adaptive design and Causal-ML models to optimize trial parameters and identify patients more likely to respond to specific therapies. PhaseV collaborates with global pharmaceutical and biotech companies, including iOMEDICO and Cancer Advances, to support personalized medicine and accelerate cancer drug development. The announcement precedes their presentation at the ESMO 2024 Congress.
Partners
/PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today that company executives will present...
PhaseV, a pioneer in software and machine learning for clinical trial optimization, announced that its executives will present at four leading industry events in September and October. The presentations will cover various topics related to the efficacy of immunotherapy alternatives, model-guided parameter optimization, and Bayesian adaptive trials. PhaseVs machine learning-based platform enables the design and execution of dynamic adaptive clinical trials, enhancing trial success rates by detecting hidden signals in clinical data. The company aims to bring new treatments to patients more efficiently. The events include the ESMO Congress, ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Italian Tech Week, and Bayesian Biostatistics Conference Bayes 2024.
CustomersPartners
PhaseV raises $15 million to optimize clinical trials with casual machine learning | CTech
PhaseV, a company that develops machine learning technology for optimizing clinical trial design and analysis, has raised $15 million in funding. The round was led by Viola Ventures and Exor Ventures, with participation from LionBird and a group of angel investors. PhaseVs platform allows clinical development teams to retrospectively analyze and optimally design studies, as well as adapt in real-time throughout the trial. The new funding will be used to further advance the platform and expand the companys reach to additional pharma, CRO and biotech companies in Europe and the U.S.
InvestmentExpand
